Needham analyst Michael Matson has reiterated their bullish stance on BSX stock, giving a Buy rating yesterday.
Michael Matson has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong performance and growth potential. The company’s first-quarter results for 2025 exceeded expectations in both revenue and earnings per share, prompting an upward revision of its financial guidance for the year. Despite a slight deceleration in organic growth, this was attributed to fewer selling days in the quarter, and the company continues to benefit from robust performance in its key product lines, FARAPULSE and WATCHMAN.
Boston Scientific also demonstrated improved operational efficiency, with notable year-over-year increases in both gross and operating margins. While the company anticipates a tariff impact in the latter half of the year, it expects to mitigate this through enhanced revenue growth, reduced discretionary spending, and favorable currency effects. Additionally, the transition in the CFO position is expected to be smooth, with Jon Monson taking over the role. These factors collectively support the positive outlook and the decision to maintain a Buy rating, along with a raised price target.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $115.00 price target.
Based on the recent corporate insider activity of 131 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.